Literature DB >> 9768618

Effective lysis of HIV-1-infected primary CD4+ T cells by a cytotoxic T-lymphocyte clone directed against a novel A2-restricted reverse-transcriptase epitope.

P Shankar1, H Sprang, J Lieberman.   

Abstract

Most HIV-specific cytotoxic T-lymphocyte (CTL) epitopes have been identified using peptide-pulsed and recombinant vaccinia virus-infected targets. These systems may not accurately reflect the ability of epitopes to be presented by HIV-infected T cells. Recent studies suggest, in fact, that some CTL epitopes are poorly presented on HIV-infected cells. In this study, we have identified a novel A2.1-restricted HIV reverse-transcriptase (RT) epitope and investigated the presentation of this epitope by HIV-infected primary CD4+ T cells and T-cell lines. A CD8+ CTL clone, isolated from a seropositive subject that recognized a novel A2-restricted epitope KYTAFTIPSI (aa 293-302) in RT, was used for these studies. Primary CD4+ T cells and the CD4+ T-cell line T1 were infected with virus from T1-nPLAP, a cell line stably transfected with HXB-nPLAP, a molecular construct of HIV linked to a placental alkaline phosphatase (PLAP) marker gene. A uniformly infected cell population, obtained by immunomagnetic selection for PLAP expression, was used as targets in CTL assays. HIV-infected T cells were lysed by CTL recognizing this RT epitope as effectively as peptide-pulsed targets. This suggests that some RT epitopes are good targets for CTL recognition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768618     DOI: 10.1097/00042560-199810010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  2 in total

1.  Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation.

Authors:  L A Trimble; P Shankar; M Patterson; J P Daily; J Lieberman
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Authors:  Carlum Shiu; Coleen K Cunningham; Thomas Greenough; Petronella Muresan; Victor Sanchez-Merino; Vincent Carey; J Brooks Jackson; Carrie Ziemniak; Lawrence Fox; Marvin Belzer; Stuart C Ray; Katherine Luzuriaga; Deborah Persaud
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.